LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Non-small cell lung cancer (NSCLC) has high mortality with limited effective therapies.
• Chimeric antigen receptor (CAR) T-cell therapy is successful in hematologic cancers but less so in solid tumors due to target limitations.
• Lung-specific X (LunX) is identified as an overexpressed antigen in lung cancer cells.

Purpose of the Study:

• To develop and evaluate a CAR T-cell strategy targeting LunX for NSCLC treatment.
• To assess the efficacy of CAR^LunX T-cells in vitro and in vivo models of NSCLC.

Main Methods:

• Construction of CAR T-cells engineered to recognize and target LunX.
• In vitro testing of CAR^LunX T-cells for cytotoxicity and cytokine production against NSCLC cell lines.
• In vivo studies using xenograft models of metastatic lung cancer and patient-derived lung cancer models to evaluate therapeutic effects.

Main Results:

• CAR^LunX T-cells demonstrated specific recognition and killing of LunX-positive NSCLC cells in vitro, along with cytokine secretion.
• Adoptive transfer of CAR^LunX T-cells led to regression of established lung cancer xenografts and prolonged survival.
• Tumor growth suppression and significantly prolonged survival were observed in patient-derived xenograft models after CAR^LunX T-cell therapy.

Conclusions:

• Targeting LunX with CAR T-cells represents a promising preclinical immunotherapeutic strategy for NSCLC.
• CAR^LunX T-cells show potential for treating NSCLC by infiltrating tumors and exerting cytotoxic effects.
• These findings provide a foundation for further development of LunX-targeted CAR T-cell therapy for lung cancer patients.